New members joined the RDAF in October 2018

18 Oct, 2018

In October 2018, Dipharma, the Swiss Society for Porphyria and Prof. Dr med. Philipp Latzin of the Inselspital University hospital’s children clinic in Bern joined the Rare Disease Action Forum (RDAF), which now hosts a total of 19 members. With our multistakeholder approach, the RDAF contributes towards the development of sustainable solutions to improve the situation of patients with rare diseases in Switzerland.

Joint statement on the KVV/OAMal and KLV/OPAS revision

The RDAF co-signed a joint statement with other stakeholders on the revision of the Health Insurance Ordinance (KVV/OAMal) and Health Benefits Ordinance (KLV/OPAS). The statement highlights the potential negative impacts of the revision, including the following: -...

The Rare Disease Action Forum (RDAF) advocates for a fair and rapid access to high-quality treatment for patients with rare diseases in Switzerland.

In line with this concern, the RDAF would like to draw attention to the fact that the planned revision of the Health Insurance Ordinance (KVV), contrary to its stated objective, threatens patients’ access to treatment. Read our media release here.